Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson Sells 50,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $7.73, for a total transaction of $386,500.00. Following the sale, the chief executive officer now owns 863,524 shares of the company’s stock, valued at $6,675,040.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, April 3rd, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.84, for a total value of $353,600.00.
• On Thursday, March 28th, Christopher Gibson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.10, for a total value of $404,000.00.
• On Wednesday, March 6th, Christopher Gibson sold 36,319 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.86, for a total transaction of $430,743.34.
• On Wednesday, February 7th, Christopher Gibson sold 48,272 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.22, for a total transaction of $445,067.84.

Recursion Pharmaceuticals Stock Up 0.6 %

Shares of Recursion Pharmaceuticals stock opened at $8.84 on Friday. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $16.75. The company has a fifty day moving average of $9.97 and a 200 day moving average of $9.16.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. The firm had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in RXRX. Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the first quarter worth $26,000. National Bank of Canada FI boosted its holdings in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Recursion Pharmaceuticals by 116.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,237 shares of the company’s stock valued at $40,000 after purchasing an additional 2,817 shares in the last quarter. First Horizon Advisors Inc. bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth about $47,000. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Recursion Pharmaceuticals by 25.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,123 shares of the company’s stock worth $77,000 after buying an additional 2,050 shares in the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on RXRX shares. KeyCorp upped their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Needham & Company LLC restated a “buy” rating and issued a $17.00 price target on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Finally, TD Cowen began coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They issued a “market perform” rating on the stock. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.